Aim Any aesthetic procedure in the head and/or in the face might have an impact on psychological status of the treated participants. Aim of this study was to investigate whether Botulinum toxin treatment for aesthetic purpose in the face influences on the level of happiness, depression and anxiety. Methods This prospective cohort observational study included 30 participants, who were treated by botulinum toxin (Botox) due to aesthetic corrections. The treatment included laugh lines, frown lines and horizontal forehead lines. Preprocedural, three and six months after the treatment the participants were assessed by The Oxford Happiness Questionnaire (OHQ), The Beck Depression Inventory (BDI) and The Beck Anxiety Inventory (BAI) to determine the level of happiness, anxiety and depression was used. Results Three months after the treatment by Botox the level of happiness was significantly increased (5.26±0.43 vs 4.3±0.34; p<0.0001). The levels of depression (7.6±6.0 vs 14.2±8.3; p<0.0001) and anxiety (8.8±6.3 vs 16.4±8.8; p<0.0001) were significantly decreased compared with preprocedural level. Significant increased level of happiness and decreased levels of depression and anxiety remained six months after the treatment, but attenuated. A dose of applied botulinum toxin was negatively correlated with the level of depression (r = -0.394; p=0.0421) and anxiety (r = -0.387; p=0.0302). Conclusion Botulinum toxin treatment for aesthetic purpose in the face positively influences psychological status of the treated individual in the short-therm.
Aim: To assess the impact of cognitive impairments on various domains of quality of life in patients with multiple sclerosis (MS). Methods: This prospective study included 135 MS patients and 50 healthy controls. Participants were divided into three groups: patients with MS for more than one year (n=85), newly diagnosed MS patients (n=50), and healthy individuals (n=50). Neurocognitive assessments included the Mini-Mental State Examination, Wechsler Intelligence Scale, Revised Beta Test, Raven's Coloured Progressive Matrices, Wechsler Memory Scale, Rey-Osterrieth Complex Figure Test, Verbal Fluency Test, Audio-Verbal Learning Test, and the SF-36 Quality of Life Scale. Results: Cognitive impairments were present in 40–60% of MS patients, with memory dysfunctions being the most prominent (30–60%). Longer disease duration was associated with poorer visuospatial, visuoconstructive, and attention-related abilities. Patients also showed reduced logical and working memory. Quality of life was significantly lower in MS groups compared to controls, with a notable correlation between cognitive impairment and decreased MMSE scores. Conclusion: Cognitive impairments in MS patients, particularly those affecting memory, executive functioning, and attention, significantly reduce quality of life. Cognitive testing should be considered essential in assessing disease severity and treatment planning.